Navigation Links
NIH to join multi-center clinical trial of new tuberculosis vaccine
Date:1/31/2012

Rockville, MD, USA Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

NIH has a long history of supporting TB vaccine development. However, this is the first time that NIH is leveraging its HIV/AIDS clinical trial networks to advance a tuberculosis vaccine candidate. Along with the recent announcement of NIAID's new partnership in a Phase III TB drug trial, this collaboration follows the NIAID plan to leverage infrastructure originally intended for HIV-related clinical trials to also advance tuberculosis vaccine and therapeutic research for both HIV uninfected and infected populations.

One-third of the world's population is infected with tuberculosis. Infants and people who are immune compromised, including those with HIV infection, are at higher risk of developing active TB. Safe and effective vaccines hold promise for protecting these at-risk populations.

"NIAID's involvement in this important clinical trial will maximize return on U.S. government investment in clinical research infrastructure while accelerating progress against the world's deadliest infectious disease after HIV/AIDS," said Mary Woolley, CEO and President of Research!America, the nation's largest not-for-profit public education and advocacy alliance committed to research.

The clinical trial, which began in October 2010, has already enrolled infants at three sites in Kenya, South Africa and Mozambique. The goal of the trial is to evaluate the safety and efficacy of vaccine candidate AERAS-402/Crucell Ad35 in HIV-uninfected infants. Significant support for the trial is also provided by the European and Developing Countries Clinical Trials Partnership (EDCTP) and European Member States.

The first NIAID-supported site to join the clinical trial is the Perinatal HIV Research Unit (PHRU) located in Soweto, South Africa at the Chris Hani Baragwanath Hospital. The research site is a member of NIAID-funded clinical trial networks including the HIV Vaccine Trials Network (HVTN), the HIV Prevention Trials Network (HPTN) and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT).

"Our novel collaboration with NIAID comes as multiple TB vaccine candidates are poised to enter efficacy trials requiring thousands of participants and significant investment, as well as complex infrastructure and sophisticated expertise," said Jim Connolly, President and CEO of Aeras.

"We are grateful for the partnership of one of the most well-respected biomedical research institutes in the world, and the opportunity to utilize well-established clinical sites," he added.


'/>"/>
Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. Parkinsons treatment shows positive results in clinical testing
2. Kessler Foundation and USC collaborate on clinical virtual reality for disability research
3. Clinical trial demonstrates that rilonacept significantly reduces gout flares
4. Many NIH-funded clinical trials go unpublished over 2 years after completion
5. Demographic and clinical factors appear associated with survival in patients with Parkinsons disease
6. Journal of Clinical Virology assembles papers on HIV diagnostic testing algorithms
7. Potential concern about drugs in clinical trial
8. SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome
9. First genome sequencing clinical trial for triple negative cancer points to new treatments
10. When prophecy fails: How to better predict success in HIV prevention clinical trials
11. Pycnogenol® found to improve memory and test scores in college students in new clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused on treating ... its dental gel that shows significant reduction in plaque levels and gum inflammation and ... was conducted at the Beckman Laser Institute at UC Irvine and has been published ...
(Date:1/17/2017)... ... 17, 2017 , ... The Sharie Withers Agency, a full-service ... latest beneficiary of their thriving community involvement program. The current campaign fundraises to ... dreams of terminally ill patients. Donations to this worthy cause may now be ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global ... a new agreement as part of a long-term extension of their media partnership. The ... airing of some of the sport’s premier events exclusively on FloWrestling.com as well as ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), ... and pathology services for evaluating risks of cancer, announced ... 13, 2017 from the NASDAQ Listing Qualifications notifying the ... of the NASDAQ Stock Market to maintain a minimum ... The letter noted that for the last 10 days ...
(Date:1/17/2017)... Research and Markets has announced the addition ... their offering. ... The global laparotomy sponges market to grow at a CAGR of ... Sponges Market 2016-2020, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, ... cancer care, and University Hospitals Seidman Cancer Center ... by making genomic data, advanced molecular analysis and ... researchers, physicians and healthcare providers. ... provide genomic and transcriptomic sequencing and analysis for ...
Breaking Medicine Technology: